Preferred Partners

 

 

Regeneron Pharmaceuticals is the leader in human antibody technologies and have built a pipeline of antibody drug candidates against both novel and validated drug targets in diseases ranging from cancer to rheumatoid arthritis. At Regeneron they make it their business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Their pursuit has one singular intent – to improve therapeutic outcomes for patients.

Detecting DME in its early stages is important in the fight against vision loss and possible blindness. Knowing the risk factors associated with DME can help you identify which patients should be referred to their optometrist, general ophthalmologist, or retina specialist.

The Regeneron: Diabetic Macular Edema (DME) Toolkit can be accessed by clicking here.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

Case managers, among other health care providers, recognize that if patients with diabetes adhered to treatment recommendations, they could manage long-term diabetes-related complications.

To access the AstraZeneca: Diabetes Case Manager Toolkit click here.